Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-120751
Filing Date
2024-11-04
Accepted
2024-11-04 16:31:20
Documents
54
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ubx-20240930.htm   iXBRL 10-Q 2145850
2 EX-31.1 ubx-ex31_1.htm EX-31.1 16627
3 EX-31.2 ubx-ex31_2.htm EX-31.2 16628
4 EX-32.1 ubx-ex32_1.htm EX-32.1 15479
  Complete submission text file 0000950170-24-120751.txt   8076535

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20240930.xsd EX-101.SCH 1147344
56 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20240930_htm.xml XML 1386554
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38470 | Film No.: 241424081
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)